



Date: 30/05/2023

The General Manager Department of Corporate Services BSE Limited Phiroze Jeejabhoy Towers Dalal Street, Fort Mumbai - 400 001	The Manager Listing Department National Stock Exchanges of India Limited Exchange Plaza , 5 th Floor, Plot No.C/1, G Block, Bandra- kurla Complex, Bandra(East) Mumbai – 400 051
Scrip Code : 523796	Scrip Code : VICEROY

Dear Sir/Madam,

Subject: Compliance under Regulation 47 of the SEBI Listing Obligation and Disclosure Requirements) Regulation, 2015.

Pursuant to the provision of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the copy of newspaper advertisement of the Audited Financial Results of the Company for the quarter and year ended on 31st March 2023 published today i.e. 30th May, 2023 in Financial Express (in English) and Navatelangana (In Telugu).

This is for your information and record.

Thanking You,

Yours Faithfully,

For Viceroy Hotels Limited

Dr. Govindarajula Venkata Narasimha Rao
Resolution Professional for Viceroy Hotels Limited
IP Registration No. IBBI/IPA-003/IP-N00093/2017-18/10893

VICEROY HOTELS LIMITED

Regd. Office: # Plot No. 20, Sector-I, 4th Floor, Huda Techno Enclave, Sy. No. 64, Madhapur, Hyderabad - 500 081.
Phone: 91-40-2311 9695 Fax : 91-40-4034 9828 Website: www.viceroyhotels.in
CIN : L55101TG1965PLC001048

Medicamen Biotech Ltd.

Regd. Office: 1586, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL1993PLC056594
E-mail: cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2023 (all figures are in Rs. Lacs, except EPS)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022	Audited 31.03.2023	Audited 31.03.2022
1	Total income from operations (net)	3749.48	2309.14	14034.62	11716.53	14332.96	11716.53
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	464.70	322.84	1733.28	1810.35	1704.50	1809.42
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	404.60	275.47	1500.20	1490.64	1472.85	1489.71
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	404.60	275.47	1500.20	1490.64	1472.85	1489.71
6	Equity Share Capital	1265.11	1221.66	1265.11	1221.66	1265.11	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation) Basic: Diluted:	3.25 3.25	2.25 2.25	12.04 12.04	12.20 12.20	11.82 11.82	12.19 12.19

Notes:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2023. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - 'Earning per Share'.
- The other expenses and Employee benefits expenses includes Rs. 3.50 Crores approximately incurred during Financial Year 2022-23 on creating domestic marketing network for Oncology products.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- The figures of the last quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figure upto the period end of the third quarter of the relevant financial year, which were subject to limited review.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date: 29.05.2023

ALPINE HOUSING DEVELOPMENT CORPORATION LIMITED

CIN : LB5110KA1992PLC013174
Regd. off: 302, Alpine Arch, No. 10, Langford Road, Bangalore 560 027, Karnataka, INDIA
WWW.alpinehousing.com, e-mail: contact@alpinehousing.com Fax: 91-80-22128357, Tel: +91-80-40473500
Extract of the audited Standalone Financial Results for the quarter and year ended March 31, 2023
Rs in lakhs except EPS

Sl. No.	Particulars	Quarter ended		Year Ended	
		31.3.2023	30.12.2022	31.3.2022	31.3.2022
		audited	Un audited	audited	audited
1	Total Income from Operation(Net)	1836.93	868.77	1052.46	4880.25
2	Net profit for the period (before Exceptional and Extraordinary items and tax)	180.73	78.29	32.36	282.06
3	Net profit for the period before Tax (after exceptional and extraordinary items)	180.44	78.05	32.01	277.76
4	Net profit for the period after tax (after Exceptional and extraordinary items)	148.34	64.86	22.85	237.53
5	Total comprehensive income for the period (comprising profit for the period(after tax) and other comprehensive income (after tax))	148.34	64.86	22.85	237.53
6	Equity Share Capital	1732.1898	1732.1898	1732.1898	1732.1898
7	Earnings per share(Rs. 10/- each) a) Basic b) Diluted	0.90 0.90	0.37 0.37	0.13 0.13	1.37 1.37
8	Debits	2156.26	2812.39	4419.05	2156.26
9	Net worth	7593.84	7445.50	7356.31	7593.84
10	Debt Equity ratio	0.28	0.38	0.60	0.28
11	Debt service coverage ratio	0.31	0.16	0.19	0.31
12	Interest service coverage ratio	1.77	1.42	1.45	1.77
13	Current Ratio	2.14	2.01	2.68	2.14
14	Long Term debt to working capital	0.15	0.18	0.37	0.15
15	Bad debts to A/c Receivables	0.83	0.82	0.59	0.83
16	Current liability ratio	0.15	0.18	0.28	0.15
17	Total debts to total assets	1.26	0.79	1.29	1.26
18	Debtors turnover	0.77	0.43	0.57	0.77
19	Inventory turnover	11.91%	14.56%	8.88%	9.61%
20	Operating Margin %	8.08%	7.47%	2.15%	4.87%
21	Net Profit Margin %				

Notes:

- The above is an extract of the detailed format of audited Financial results for the quarter and year ended 31 March 2023 filed with the stock exchange under regulation 33 of SEBI(Listing obligations and disclosure requirements) Regulations 2015. The full format of the audited financial results are available on the company website www.alpinehousing.com and the stock exchange website www.bseindia.com.
- The results are prepared in accordance with IND AS prescribed under section 133 of the Companies act 2013 For and on behalf of the Board of Directors
Alpine Housing Development Corporation Limited
Sd
S.A.Kabeer
Chairman and Managing Director
DIN 101664782

Place : Bangalore
Date : 29 May 2023

CENLUB INDUSTRIES LIMITED

Plot No-233-234, Sector-58, Ballabgarh, Faridabad-121004, (Haryana)
Ph: 91 -8826794470-73 Fax: 91 (129) 2307263 Website: http://www.cenlub.in
Corporate Identity Number: L67120HR1992 PLC035087 Email: investors@cenlub.in
Statement of Audited Financial Results for the quarter and Year ended 31 March 2023
(Rs. in Lakhs)

Sr. no.	Particulars	Quarter Ended		Year Ended	
		31-Mar-23	31-Mar-22	31-Mar-23	31-Mar-22
		(Audited)	(Audited)	(Audited)	(Audited)
1	Total income from operations (net)	1,163.78	1,728.57	5,519.93	5,382.16
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	36.13	377.99	903.11	866.82
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	36.13	377.99	903.11	866.82
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	20.65	334.59	699.43	700.38
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax))	17.04	330.98	665.81	699.54
6	Equity Share Capital (in Qty)	466.29	466.29	466.29	466.29
7	Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of previous year)			4,254.13	3,588.34
8	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) Basic : Diluted:	0.44 0.44	7.18 7.18	14.36 14.36	15.02 15.02

Note:

- The above results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 29th May, 2023.
- The financial results are prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act 2013, read together with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
- The Board of Directors of the company has considered to skip the dividend for the year.
- The Financial results of the company for the quarter year ended March 31, 2023 are also available on the Company's website (www.cenlub.in) and on the website of BSE (www.bseindia.com)
- Previous period figures have been regrouped / reclassified, wherever necessary, to make them comparable with current period figures.

FOR CENLUB INDUSTRIES LIMITED
Sd/-
ANSH MITTAL
EXECUTIVE DIRECTOR
DIN: 00041986

Place : Faridabad
Dated : May 29, 2023

BROOKS LABORATORIES LIMITED

CIN No.: L24232HP2002PLC000267, Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101, E-mail : investors@brookslabs.net | Website: www.brookslabs.net

EXTRACTS OF STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2023 (₹ in Lakhs)

Sr. No.	Particulars	Standalone				Consolidated					
		Quarter Ended		Year Ended		Quarter Ended		Year Ended			
		31-Mar-23	31-Dec-22	31-Mar-22	31-Mar-23	31-Mar-22	31-Mar-23	31-Mar-22	31-Mar-23		
1	Total income from operations (net)	1,263.32	1,206.30	2,167.41	5,564.52	7,791.48	1,263.32	1,539.53	2,864.49	6,340.80	9,198.63
2	Net Profit/(Loss) for the period from ordinary activities (Before Share of Profit/(Loss) of Associate, tax, Exceptional and/or Extraordinary items)	(72.00)	(208.22)	5.07	(819.12)	66.60	(72.00)	(1,153.85)	(651.93)	(3,542.49)	(2,389.76)
3	Net Profit/(Loss) for the period before tax (after Share of Profit/(Loss) of Associate, Exceptional and/or Extraordinary items)	(72.00)	(208.22)	5.07	(819.12)	66.60	(429.85)	(1,117.83)	(651.93)	(3,837.82)	(2,389.76)
4	Net Profit / (Loss) for the period after tax (after Share of Profit / (Loss) of Associate, Exceptional and /or Extraordinary items)	(72.00)	(208.22)	5.07	(819.12)	66.60	(429.85)	(948.16)	(593.53)	(3,105.41)	(1,931.25)
5	Total Comprehensive Income for the period [(comprising profit or (loss) for the period (after tax) and other Comprehensive income (after tax)]	(75.29)	(208.22)	26.60	(822.41)	79.26	(433.14)	(948.16)	(578.12)	(3,108.71)	(1,924.71)
6	Equity Share Capital(Face Value ₹10/- per share)	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28	2,470.28
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.	4,030.01	4,030.02	3,950.76	4,030.01	3,950.76	6,278.72	6,278.72	5,444.56	6,278.72	5,444.56
8	Earnings per share (of ₹ 10/- each) (not annualised) (a) Basic (b) Diluted	(0.29) (0.29)	(0.84) (0.84)	0.02 0.02	(3.32) (3.32)	(0.27) (0.27)	(1.74) (1.74)	(2.03) (2.03)	(1.46) (1.46)	(12.57) (12.57)	(7.82) (7.82)

Notes: The above is an extract of the detailed format of Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the Standalone and Consolidated Financial Result for the quarter and year ended 31st March, 2023 is available on www.bseindia.com, www.nseindia.com and www.brookslabs.net

For and on behalf of the Board
Sd/-
Kaushalya Singh (DIN: 09244596)
Whole Time Director

Place : Mumbai
Date : 29th May 2023

D S Kulkarni Developers Limited

CIN: L45201PN1991PLC063340
Reg. Office: 1187/60, DSK House, J M Road, Shivajinagar, Pune - 411 005
Address for communication: Office No.40, 2nd Floor, Sanas Plaza, Bajirao Road, 1302 Shukrawar Peth, PUNE - 411002
Email Id: ip.dskdl@gmail.com

Extract of Standalone Audited Financial Results for the Quarter and Financial Year Ended 31st March, 2023 (Amount in Lakhs)

Sl. No.	Particulars	Quarter ended	Previous Year	Year	Previous
		31/03/2023	Quarter Ended	Ended	Year Ended
		Audited	31/03/2022	31/03/2023	31/03/2022
1	Total income from operations	NIL	NIL	NIL	4.59
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(111.45)	(99.97)	(306.61)	(266.46)
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(111.45)	(99.97)	(4,867.38)	(266.46)
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(4,672.22)	(99.97)	(4,867.38)	(266.46)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	NIL	NIL	NIL	NIL
6	Paid Up Equity Share Capital (Face Value of Rs. 10/- per share)	2,580.1	2,580.1	2,580.1	2,580.1
7	Other Equity (Reserves) (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	18,802.47	23,669.85
8	Earnings Per Share (before /after extraordinary items) (of Rs. 10/- each) (not annualised) (a) Basic: (b) Diluted:	(18.11) (18.11)	(0.39) (0.39)	(18.87) (18.87)	(1.03) (1.03)

Note: a) The above is an extract of the detailed format of Quarterly Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full formats of the Quarterly/Annual Financial Results are available on the www.bseindia.com and www.nseindia.com

For D S Kulkarni Developers Limited
Sd/-
Name: Manoj Kumar Agarwal
Designation: Resolution Professional
(IBBI/IPA-001/IP-P00714/2017-18/11222
AFA No. AA1/11222/02/301123/104973 valid till 30/11/23

Date : 29/05/2023
Place : Mumbai

VICEROY HOTELS LIMITED

Regd. Office: Plot No.20, Sector-I, Survey No.64, 4th Floor, HUDA Techno Enclave, Hyderabad - 500 081, Telangana.
Phone No.040-23119695 / 40349999 Fax.No.040-40349828,
email: secretarial.viceroy@gmail.com, www.viceroyhotels.in, CIN:L55101TG1965PLC001048

STATEMENT OF STANDALONE & CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2023 (Rs. In Lakhs)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED				
		Quarter Ended	Quarter Ended	Year Ended	Year Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended	
		31-03-2023 (Audited)	31-12-2022 (Unaudited)	31-03-2022 (Audited)	31-03-2023 (Audited)	31-03-2022 (Audited)	31-12-2022 (Unaudited)	31-03-2022 (Audited)	31-03-2023 (Audited)	
1	Income									
	(a) Revenue from operations	2970.39	2481.84	1056.56	9,639.86	4,298.06	3,216.73	2,876.55	1,989.16	11,595.30
	(b) Other Income	60.81	90.12	169.49	235.44	399.55	95.54	161.99	198.58	404.50
	Total Income	3031.2	2,571.96	1,226.05	9,875.30	4,697.61	3312.27	3,038.54	2,187.74	11,999.80
2	Expenses									
	(a) Cost of materials consumed	329.72	324.9	247.58	1,324.40	967.02	611.96	771.59	1,474.32	3,386.61
	(b) Employee benefits expense	555.32	485.74	357.52	1,898.55	1,321.06	558.41	536.78	415.38	2,053.48
	(c) Fuel, Power and Light	233.30	232.92	137.51	916.77	521.16	233.30	232.92	126.19	916.77
	(d) Finance Cost	44.99	0.00	24.86	86.24	43.19	45.09	0.14	46.51	87.05
	(e) Depreciation and amortisation expense	210.87	211.13	212.49	844.26	849.94	214.64	214.83	268.06	859.36
	(f) Other expenses	1512.30	1408.38	599.07	4,282.44	1,897.50	1,636.32	1,523.90	747.35	4,651.54
	Total Expenses	2886.49	2,663.07	1,579.03	9,352.65	5,599.87	3299.72	3,280.16	3,077.81	11,954.81
3	Profit / (Loss) before Exceptional items and Tax	144.71	(91.11)	(352.98)	522.65	(902.26)	12.55	(241.62)	(890.07)	44.99
4	Exceptional items	-	-	-	-	-	-	-	-	-
5	Profit / (Loss) before Tax	144.71	(91.11)	(352.98)	522.65	(902.26)	12.55	(241.62)	(890.07)	44.99
6	Tax expense									
	- Current Tax	-	-	-	-	-	-	-	-	-
	- Deferred Tax	11.54	(11.54)	20.46	46.40	82.30	12.72	12.65	(9.89)	50.48
7	Profit / (Loss) for the period from Continuing operations	133.17	(102.65)	(373.44)	476.25	(884.56)	(0.17)	(254.27)	(880.18)	(5.49)
8	Extraordinary Item	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income	-	-	-	-	-	-	-	-	-
	i) items that will not reclassified to Profit & Loss Account	-	-	-	-	-	-	-	-	-
	ii) items that will be reclassified to Profit & Loss Account	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income for the period	133.17	(102.65)	(

